builderall

CONFERENCE INFORMATION

Conference Description

This accredited education activity delivers a comprehensive, practice-focused update on the use of systemic therapies in oncology, with emphasis on immunotherapy, targeted agents, and personalized treatment strategies. Designed to support clinical decision-making in the management of gastrointestinal, genitourinary, lung, and breast cancers, the lecture series will feature evidence-based presentations, expert panels, multidisciplinary tumor boards, and interactive, case-based discussions. Participants will explore real-world applications of novel agents such as HER2-directed therapies, antibody-drug conjugates, FGFR and PARP inhibitors, and targeted therapies for RET, BRAF, and KRAS mutations. Through collaborative dialogue and expert insight, learners will enhance their ability to integrate emerging clinical data and molecular diagnostics into personalized care plans, improve patient outcomes, and navigate ongoing therapeutic controversies in oncology practice.

Target Audience

This activity is intended for medical oncologists, oncology pharmacists, oncology nurses, nurse practitioners (NPs), and clinical nurse specialists, physician associates/assistants (PAs), hematology/oncology fellows and residents and other healthcare professionals involved in the care of patients with cancer.

Learner Objectives

At the conclusion of this activity, participants will be better able to:

  • Apply emerging clinical data on novel systemic therapies—including immunotherapies, antibody-drug conjugates, and PARP inhibitors—to treatment strategies for patients with GI, GU, lung, and breast cancers.

  • Interpret molecular and biomarker testing results (e.g., HER2, FGFR, RET, BRAF, KRAS) to guide therapeutic selection and personalize oncology care.

  • Evaluate the safety profiles and mechanisms of action of newly approved agents and investigational treatments and integrate this knowledge into patient counseling and monitoring strategies.

  • Assess the role of multidisciplinary collaboration in managing complex cancer cases through tumor board participation and interprofessional planning.

  • Describe the design and goals of ongoing clinical trials, and identify patients who may be appropriate candidates for enrollment based on disease characteristics and therapeutic needs.